沃尔格林-联合博姿 2023年度报告

2024Board of Directors As of August 31, 2024From left to right, sitting then standing Inderpal S. Bhandari Janice M. Babiak Stefano Pessina Executive Chairman,Walgreens Boots Alliance, Inc. Former Managing Partner,Ernst & Young LLP Former Global Chief Data Officer,International Business MachinesCorporation Bryan C. Hanson John A. Lederer Ginger L. Graham Senior Advisor, Sycamore Partners Chief Executive Officer,Solventum Corporation Lead Independent Director,Walgreens Boots Alliance, Inc.Former President and Chief ExecutiveOfficer, Amylin Pharmaceuticals William H. Shrank, M.D. Robert L. Huffines Venture Partner, Andreessen Horowitz,Bio+Health Team Former Global Chairman, InvestmentBanking at J.P. Morgan Chase & Co. Valerie B. Jarrett Nancy M. Schlichting Chief Executive Officer,The Barack Obama Foundation Timothy C. Wentworth Former Chief Executive Officer,Henry Ford Health System Chief Executive Officer,Walgreens Boots Alliance, Inc. Thomas E. Polen Chairman, President and ChiefExecutive Officer, Becton, Dickinson andCompany(BD) UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 10-KÍANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2024‘TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 WALGREENS BOOTS ALLIANCE, INC.(Exact name of registrant as specified in its charter) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.YesÍNo‘Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports) and (2) has been subject to such filing requirements for the past 90 days.YesÍNo‘Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files).YesÍNo‘Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.Large accelerated filerÍAccelerated filer‘ Smaller reporting company‘Emerging growth company‘If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for Non-accelerated filer‘ complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.‘Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of theeffectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) bythe registered public accounting firm that prepared or issued its audit report.ÍIf securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.‘Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to§240.10D-1(b).‘ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes‘NoÍAs of February 29, 2024, the aggregate market value of Walgreens Boots Alliance, Inc. common stock held by non-affiliates (basedon the closing transaction price on Thursday, February 29, 2024) was approximately $15.2 billion. As of October 8, 2024, there were864,617,130 shares of Walgreens Boots Alliance, Inc. common stock outstanding.DOCUMENTS INCORPORATED BY REFERENCE Portions of the definitive proxy statement for our Annual Meeting of Stockholders, to be filed with the Securities and ExchangeCommission within 120 days after the end of the fiscal year ended August 31, 2024 are incorporated by reference into Part III of thisForm 10-K as indicated herein. Walgreens Boots Alliance, Inc.Annual Report on Form 10-K Table of Contents Part I Item 1.Business1Information about our executive officers12Item 1A.Risk factors15Item 1B.Unresolved staff comments40Item 1C.Cybersecurity40Item 2.Properties42Item 3.Legal proceedings43Item 4.Mine safety d